Cartesian Therapeutics, Inc. Shareholders' Equity
Cartesian Therapeutics, Inc. (RNAC) had Shareholders' Equity of -$125.23 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent -$125.23M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$148.12M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$126.24M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$35.84M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$125.23M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$148.12M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | -$126.24M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$35.84M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | -$2.53M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | -$21.79M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | -$6.80M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $752.00K 10-Q · filed 2025-11-06 | |
| 2024-06-30 | -$101.46M 10-Q · filed 2025-11-06 | |
| 2024-03-31 | -$116.80M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | -$440.18M 10-K · filed 2026-03-09 | |
| 2023-09-30 | $60.33M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $65.45M 10-Q · filed 2024-11-07 | |
| 2023-03-31 | $74.58M 10-Q · filed 2024-11-07 | |
| 2022-12-31 | $93.83M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $84.91M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $89.61M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $55.76M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $22.52M 10-K · filed 2024-03-07 | |
| 2021-09-30 | -$18.73M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$4.22M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | -$19.57M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | -$18.01M 10-K · filed 2024-03-07 | |
| 2020-09-30 | -$7.38M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$13.05M 10-Q · filed 2021-11-09 | |
| 2020-03-31 | -$8.76M 10-Q · filed 2021-11-09 | |
| 2019-12-31 | $8.40M 10-K · filed 2023-03-02 | |
| 2019-09-30 | -$4.92M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $56.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $14.82M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | -$5.42M 10-K · filed 2022-03-10 | |
| 2018-09-30 | $7.40M 10-Q · filed 2019-11-08 | $10.00M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $21.66M 10-Q · filed 2019-11-08 | $24.26M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $38.98M 10-Q · filed 2019-11-08 | $41.58M 10-Q · filed 2018-05-09 |
| 2018-01-01 | $53.64M 10-K · filed 2019-03-15 | $56.24M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $51.81M 10-K · filed 2021-03-12 | |
| 2017-09-30 | $65.08M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $78.18M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $41.09M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $54.96M 10-K · filed 2020-03-12 | |
| 2016-09-30 | $65.44M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $68.78M 10-Q · filed 2016-08-09 | |
| 2015-12-31 | -$116.49M 10-K · filed 2019-03-15 | |
| 2014-12-31 | -$87.75M 10-K · filed 2018-03-15 | |
| 2013-12-31 | -$69.46M 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |